check_circleStudy Completed

Hepatocellular carcinoma, Treatment of advanced renal cell carcinoma

Bayer Identifier:
12386
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
2006-003530-14
EU CT Number:
Not Available
BAY43-9006/sorafenib+gem+cisplatin Phase I combination study

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

44 - 76 Years

Trial summary

Enrollment Goal
20
Trial Dates
November 2006 - March 2008
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Marienhospital Herne UniversitätsklinikHerne, 44625, Germany

Trial design

Phase I single-center, open-label, non-randomized study to determine the pharmacokinetics, safety and tolerability, and tumor response profile of sorafenib as continuous dosing in combination with gemcitabine and cisplatin in patients with Stage IIIB or Stage IV non-smallcell lung cancer or other advanced solid tumors.
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.